Skip to main content

Table 3 Overall investigator-assessed response rate to bevacizumab-based therapy according to patient age

From: Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results

Response, n (%) Age <70 years (n = 1297) Age ≥70 years (n = 480) Age <75 years (n = 1571) Age ≥75 years (n = 206)
Complete response 104 (8) 34 (7) 139 (9) 17 (8)
Partial response 645 (50) 209 (44) 734 (47) 77 (37)
Stable disease 348 (27) 139 (29) 461 (29) 72 (35)
Progressive disease 96 (7) 45 (9) 115 (7) 17 (8)
Not evaluable 41 (3) 12 (3) 122 (8) 23 (11)